Retrospective Study
Copyright ©The Author(s) 2021.
World J Clin Cases. Apr 6, 2021; 9(10): 2192-2204
Published online Apr 6, 2021. doi: 10.12998/wjcc.v9.i10.2192
Table 1 Characteristics of the patients
Clinicopathological factorTotal (n = 42)Lymph node metastasis
Residual tumor
No (n = 37)
Yes (n = 5)
P value
No (n = 29)
Yes (n = 13)
P value
Age (yr), n (%)0.9260.513
< 6016 (38.1)14 (37.8)2 (40.0)12 (41.4)4 (30.8)
≥ 6026 (61.9)23 (62.2)3 (60.0)17 (58.6)9 (69.2)
Sex (male), n (%)35 (83.3)34 (91.9)1 (20.0)< 0.001 26 (89.7)9 (69.2)0.101
Tumor location, n (%)0.3160.360
Upper stomach12 (28.6)12 (32.4)0 (0)9 (31.0)3 (23.1)
Middle stomach17 (40.5)14 (37.9)3 (60.0)13 (44.8)4 (30.8)
Lower stomach13 (30.9)11 (29.7)2 (40.0)7 (24.2)6 (46.1)
Tumor size (cm), n (%)0.2810.862
< 29 (21.4)7 (18.9)2 (40.0)6 (20.7)3 (23.1)
≥ 233 (78.6)30 (81.1)3 (60.0)23 (79.3)10 (76.9)
Gross type, n (%)0.2070.106
Protruded8 (19)8 (21.6)0 (0)6 (20.7)2 (15.4)
Flat7 (16.7)7 (18.9)0 (0)7 (24.1)0 (0)
Pitting27 (64.3)22 (59.5)5 (100.0)16 (55.2)11 (84.6)
Surgical method, n (%)0.3220.152
Distal subtotal gastrectomy26 (61.9)21 (56.8)5 (100.0)15 (51.7)11 (84.6)
Proximal subtotal gastrectomy8 (19)8 (21.6)0 (0)6 (20.7)2 (15.4)
Total gastrectomy3 (7.2)3 (8.1)0 (0)3 (10.3)0 (0)
Celiac lymph node dissection5 (11.9)5 (13.5)0 (0)5 (17.3) 0 (0)
Invasion depth, n (%)0.018 0.307
T1a19 (45.2)19 (51.4)0 (0)13 (44.8)6 (46.2)
T1b23 (54.8)18 (48.6)5 (100)16 (55.2)7 (53.8)
Histological type, n (%)0.0280.654
Differentiated27 (64.3)26 (70.3)1 (20)18 (62.1)9 (69.2)
Undifferentiated15 (35.7)11 (29.7)4 (80)11 (37.9)4 (30.8)
Number of tumor lesions, n (%)0.7100.498
Solitary41 (97.6)36 (97.3)5 (100.0)28 (96.6)13 (100.0)
Multiple1 (2.4)1 (2.7)0 (0)1 (3.4)0 (0)
Positive vascular invasion, n (%)5 (11.9)0 (0)5 (100.0)< 0.0010 (0)5 (38.5)< 0.001
Lauren classification, n (%)0.0390.532
Intestinal type22 (52.4)21 (56.8)1 (20.0)15 (51.7)7 (53.8)
Diffuse13 (31.0)9 (24.3)4 (80.0)8 (27.6)5 (38.5)
Mixed 7 (16.6)7 (18.9)0 (0)6 (20.7)1 (7.7)
Pattern of invasion, n (%)< 0.0010.001
IFN-A8 (19.0)8 (21.6)0 (0)6 (20.7)2 (15.4)
IFN-B26 (62.0)26 (70.3)0 (0)22 (75.9)4 (30.8)
IFN-C8 (19.0)3 (8.1)5 (100.0)1 (3.4)7 (53.8)
Positive horizontal resection margin, n (%)19 (45.2)18 (48.6)1 (20.0)0.22710 (34.5)9 (69.2)0.036
Positive vertical resection margin, n (%)21 (50.0)16 (43.2)5 (100.0)0.01714 (48.3)7 (53.8)0.739
Positive nerve invasion, n (%)4 (9.5)1 (2.7)3 (60.0)< 0.0010 (0)4 (30.8)0.002
eCura score, n (%)< 0.0010.007
Low-risk group24 (57.1)24 (64.9)0 (0)18 (62.1)6 (46.2)
Moderate-risk group14 (33.3)13 (35.1)1 (20.0)11 (37.9)3 (23.1)
High-risk group4 (9.6)0 (0)4 (80.0)0 (0)4 (30.7)
Degree of radical endoscopic treatment (eCura), n (%)0.4670.790
eCura-A1 (2.4)1 (2.7)0 (0)1 (3.5)0 (0)
eCura-B1 (2.4)1 (2.7)0 (0)1 (3.5)0 (0)
eCura-C111 (26.2)11 (29.7)0 (0)7 (24.1)4 (30.8)
eCura-C229 (69.0)24 (64.9)5 (100.0)20 (68.9)9 (69.2)
Ulcer, n (%)26 (61.9)22 (59.5)4 (80.0)0.37516 (55.2)10 (76.9)0.180
Range of lymph node dissection, n (%)0.4090.101
D124 (57.1)22 (59.5)2 (40.0)19 (65.5)5 (38.5)
D218 (42.9)15 (40.5)3 (60.0)10 (34.5)8 (61.5)